Dr. Mark G. Goldstein

Dr. Ralph V. Boccia is a hematologist affiliated with Sibley Memorial Hospital, Suburban Hospital, Shady Grove Adventist Hospital, Holy Cross Hospital and MedStar Georgetown University Hospital, where he is a clinical associate professor of medicine for the University, as well as the medical director of the International Oncology Network (ION) Clinical Research Program and the chairman of ION’s Medical Advisory Panel. He practices out of the Center for Cancer and Blood Disorders, of which he is the founder and medical director, located in Bethesda, Maryland and Germantown, Maryland. Dr. Boccia earned his medical degree from the Autonomous University of Guadalajara School of Medicine. He completed a residency in internal medicine at Kern Medical Center, followed by a fellowship in hematology, oncology and bone marrow transplant at the combined UCLA-Veterans Administration Program and The National Cancer Institute at the National Institutes of Health. Dr. Boccia is a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. Dr. Boccia has been listed as a Top Doctor by Washingtonian Magazine and Consumers’ Checkbook Magazine since 1992. He has also been recognized as a Super Doctor by The Washington Post Magazine and a Regional Top Doctor for Washington, D.C., Baltimore and Washington-Baltimore by Castle Connolly. Dr. Boccia has contributed to various articles with his research, published in journals such as Annals of Internal Medicine, Journal of Clinical Oncology and The Lancet. Recent News Articles and Media Coverage Bladder cancer trends in Montgomery and Prince George's counties: Welcome news - and 3 facts you need to know. NJ.com (08/16/2016) RCCA Expands to Maryland to Become One of the Nation's First Multi-State Oncology/Hematology Physician-Owned and -Operated Networks. OncLive (10/06/2015). Dr. Boccia is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Anemia, Multiple Myeloma, Thrombocytopenia, Adult Immune Thrombocytopenia, and Splenectomy. Dr. Boccia is board certified in American Board Of Internal Medicine.

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant. Dr. Narang is board certified in American Board Of Internal Medicine.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gojo is board certified in American Board Of Internal Medicine.